Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib

Most patients with tyrosine kinase inhibitor (TKI)-sensitive non-small cell lung cancer (NSCLC) eventually develop acquired resistance to TKIs. Factors that affect TKI-sensitive patient survival after progression during TKI treatment remain unknown. We attempted to identify factors that affected pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyojeong, Yun, Tak, Lee, Young Joo, Han, Ji-Youn, Kim, Heung Tae, Lee, Geon Kook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835500/
https://www.ncbi.nlm.nih.gov/pubmed/24265521
http://dx.doi.org/10.3346/jkms.2013.28.11.1595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835500/
https://www.ncbi.nlm.nih.gov/pubmed/24265521
http://dx.doi.org/10.3346/jkms.2013.28.11.1595

Ejemplares similares